TPU-0037-D;8-DEOXYLYDICAMYCIN
Compound with spectra: 1 NMR
| SpectraBase Compound ID | HxoyRAtqC2Q |
|---|---|
| InChI | InChI=1S/C47H74N4O9/c1-27(38(54)12-8-13-39(55)28(2)16-21-34(53)25-32-10-9-23-51(32)46(48)49)15-19-33(52)20-17-29(3)43(58)30(4)18-22-36-31(5)24-35-37(11-7-14-40(35)56)47(36,6)44(59)42-41(57)26-50-45(42)60/h8,12,15-17,19,24,27,30,32-40,43,52-58H,7,9-11,13-14,18,20-23,25-26H2,1-6H3,(H3,48,49)(H,50,60)/b12-8+,19-15+,28-16+,29-17+ |
| InChIKey | JFDQRTPBIZLOCU-RJVJSCBMSA-N |
| Mol Weight | 839.1 g/mol |
| Molecular Formula | C47H74N4O9 |
| Exact Mass | 838.54558 g/mol |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | CD3OD |
TPU-0037-C;30-DEMETHYL-8-DEOXYLYDICAMYCIN
(2S,4aR,4bR,8aR,10aR)-8-(2,5-Dimethoxy-3-methyl-benzyl)-2-(2-methoxy-ethoxymethoxy)-1,1,4a,7,8a-pentamethyl-1,2,3,4,4a,4b,5,6,8a,9,10,10a-dodecahydro-phenanthrene
Phenochalasin G
5,7-ditert-butyl-1,3-dicyclohexyl-8-hydroxy-quinazoline-2,4-dithione
1,3-Dimethyl-6-phenyl-7-thioxo-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione
Spiro-lingshuiolide
2-amino-4-{5-[(4-chloro-2-methylphenoxy)methyl]-2,4-dimethylphenyl}-4a,5,6,7-tetrahydro-1,3,3(4H)-naphthalenetricarbonitrile
1.alpha.-(Angeloyloxy)-6.beta.-hydroxy-8.beta.-methoxy-10.beta.H-eremophil-7(11)-en-8.alpha.,12-olide
Dispiro[9H-fluorene-9,3'-[1,4,2]oxathiazolidine-5',2''-tricyclo[3.3.1.1(3,7)]decane], 2'-phenyl-
2-(2,4-dioxo-3-phenyl-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidin-1(2H)-yl)-N-phenylacetamide
| Title | Journal or Book | Year |
|---|---|---|
| TPU-0037-A, B, C and D, Novel Lydicamycin Congeners with Anti-MRSA Activity from Streptomyces platensis TP-A0598. | The Journal of Antibiotics | 2002 |
KnowItAll NMR Spectral Library
Author: Wiley
The KnowItAll NMR Spectral Library offers a comprehensive collection of NMR reference spectra, including NMR, CNMR, and XNMR, and covers a wide range of compounds including organics, polymers, monomers, metabolites, and more. Learn more.